Kidney Transplant Matching: ABO, HLA, and Beyond — Compatibility Essentials

Kidney transplant success depends on immunologic compatibility to minimize rejection. Matching is multi-layered.

1. ABO Blood Group Compatibility

  • Identical: Best (O→O, A→A, B→B, AB→AB).
  • Compatible: O→any (universal donor); A→A/AB; B→B/AB; AB→AB only (universal recipient).
  • Incompatible: A→B/O, B→A/O, AB→A/B/O. Requires desensitization (plasmapheresis, IVIG, rituximab) — higher rejection risk.

2. HLA Matching (Human Leukocyte Antigen)

  • Class I: HLA-A, -B, -C (all nucleated cells) — CD8+ T-cell recognition.
  • Class II: HLA-DR, -DQ, -DP (APCs) — CD4+ T-cell recognition.
  • Matching level: 0–6 antigen match (A, B, DR). Zero mismatches (6/6) → best graft survival.
  • HLA-DR matching most critical for long-term survival.
  • Modern immunosuppression (tacrolimus, MMF, prednisone) reduces but doesn't eliminate HLA impact.

3. Sensitization & Antibody Assessment

  • PRA (Panel Reactive Antibody): % of donor population recipient reacts with. High PRA (>80%) = highly sensitized → harder match.
  • Donor-Specific Antibodies (DSA): Anti-HLA antibodies against donor. Preformed DSA → hyperacute/accelerated rejection. Virtual crossmatch (single antigen bead assay) predicts physical crossmatch.
  • Flow crossmatch / CDC crossmatch: Final compatibility test pre-transplant.

4. Additional Factors

  • Kidney size/function: Donor kidney mass ~ recipient metabolic demand (weight-based). Pediatric en bloc vs. adult single.
  • Age matching: Younger donors → better long-term function; older donors accepted for older recipients (Eurotransplant Senior Program).
  • CMV/EBV status: D+/R− highest risk for CMV disease / PTLD; prophylaxis/preemptive therapy.
  • ABO-incompatible (ABOi) protocols: Rituximab + plasmapheresis/IVIG + maintenance IS → outcomes approaching ABOc.

Allocation Systems

  • US: KAS (Kidney Allocation Score) — longevity matching, sensitization, geography.
  • Eurotransplant: ETKAS — HLA match, waiting time, age.

Matching balances immunologic risk, organ utility, and equity. Living donation allows optimal matching; deceased donor uses allocation algorithms.

Kidney Disease - Related Articles